Kevin Seibert | AIChE

Kevin Seibert

Eli Lilly

Kevin earned his BS, MS, and PhD in Chemical Engineering and has over 25 years’ experience working in small and ‘medium’ molecule syntheses for both Merck and Eli Lilly. Kevin was Area Head of Merck’s Natural Products Isolation pilot plant as well as technical lead at both Merck and Lilly in the engineering development organizations. He has worked on the process development and optimization of many early as well as late phase products and led the technology transfer, validation, and launch of several marketed compounds. Kevin has also led initiatives for developing enhanced filings in support of the ICH Q8, Q9, Q10 and Q11 guidelines. Most recently, Kevin is responsible for the engineering design and implementation of Lilly’s synthetic peptide development facility. He has worked closely with an expert team to implement a strategy for synthesizing peptides using a standardized manufacturing platforms and applying the strategy to Lilly’s growing peptide portfolio. Kevin also leads the late phase development team responsible for the commercialization of Lilly’s latest phase peptide assets.

Currently Kevin is a Fellow with the American Institute of Chemical Engineers, and Chair of the PD2M forum within AIChE, a group promoting the exchange of ideas, promoting education, and driving the application of chemical engineering principles to discovery, development and manufacturing within the pharmaceutical industry.